and not used in the case of secondary lesions involving the leptomeningeal and pachymeningeal (dural) compartments; dural metastases can be further divided into epidural and subdural lesions.

REYOBIQ™ is being evaluated for the treatment of recurrent glioblastoma and leptomeningeal metastases in the ReSPECT-GBM and ReSPECT-LM clinical trials. ReSPECT-GBM is supported by an award from ...

Targeted therapies have significantly improved outcomes for patients with non-small cell lung cancer (NSCLC) with actionable mutations. However, many tumors inevitably develop drug resistance and ...

The Company recognized $5.8 million in grant revenue in the year ending December 31, 2024 and $4.9 million for the year ending December 31, 2023, which in both periods represents CPRIT’s share of the ...

On March 5, 2025, the FDA cleared an investigational new drug application for CTD402, a CD7-targeted universal CAR T-cell therapy, for the treatment of pediatric and adult patients with ...

The company says it aims to build awareness of the REYOBIQ name and logo, reinforcing its progress in developing targeted radiotherapeutics for leptomeningeal metastases and glioblastoma multiforme.

REYOBIQ™ (rhenium Re 186 obisbemeda) continues to be under clinical investigation for Leptomeningeal Metastases (LM) and Recurrent Glioblastoma (GBM) HOUSTON, March 20, 2025 (GLOBE NEWSWIRE ...

to accelerate the development of REYOBIQ for our leptomeningeal metastases (LM) program Strengthened management team with key leadership appointments: Dr. Michael Rosol as Chief Development ...